VivoCAR™ Anti-VEGFR-2 (TTAC-0001) h(CD28-41BB-CD3z) CAR saRNA (XS-0326-XU7)

Name: VivoCAR™ Anti-VEGFR-2 (TTAC-0001) h(CD28-41BB-CD3z) CAR saRNA
SKU: XS-0326-XU7
Rating: 5 (1 reviews)

Online Inquiry Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

VivoCAR™ Anti-VEGFR-2 (TTAC-0001) h(CD28-41BB-CD3z) CAR saRNA utilizes a self-amplifying RNA backbone to express the TTAC-0001 clone. In in vivo CAR-T applications, this clone is critical for its ability to disrupt tumor angiogenesis by targeting the VEGFR-2 signaling axis. The saRNA platform enables high-fidelity expression from a minimal initial load, allowing T cells to effectively reprogram in the bloodstream and migrate to the tumor vasculature, providing a dual mechanism of direct lysis and nutrient deprivation.

Add to Cart

CAR Information

Target
VEGFR-2

Target Species
Human

Antibody Clone
TTAC-0001

scFv Host Species
Human

Receptor Construction
CD28-41BB-CD3z

Generation
Third

Description of Signaling Cassetes
The third-generation CD28-41BB-CD3ζ architecture employs a sequential costimulatory strategy, where the CD28 module drives rapid initial activation and metabolic reprogramming, while the 4-1BB component sustains long-term cellular viability and mitigates exhaustion. This tandem design, anchored by the CD3ζ signaling chain, synergistically amplifies downstream signal transduction, resulting in a balanced T-cell phenotype with robust effector capacity and prolonged durability. The integrated signaling cascade thus optimizes both kinetic expansion and persistence, enhancing antitumor efficacy.

CAR saRNA Properties

Structure
Linear

Cap
Cap 1

PolyA
Segmented PolyA

Product Type
CAR IVT saRNA

Concentration
Lot specific

Buffer
1 mM Sodium Citrate, pH 6.4 (or specialized RNA storage buffer, RNase-free).

Storage
Aliquot and store at -80°C. Avoid freeze/thaw cycles.

Handling
Thaw and work with RNA on ice. Upon first use, pulse spin before opening and aliquot into single use portions. DO NOT vortex. Use only certified RNase-free reagents and consumables with proper RNase-free technique. Use of barrier tips is recommended. Avoid freeze/thaw cycles. DO NOT mix with media containing serum unless first complexed with a stabilizing transfection reagent.

saRNA Quality Control

IVT Vector Sequencing
Pass

IVT Vector Enzyme Digestion
Pass

Purity OD260/280
Pass

RNA Length and Integrity Assessment (Determined by Denaturing Agarose Gel Electrophoresis)
Pass

RNA Sequence Assessment
Pass

Endotoxin (<10 EU/mg)
Pass

In Vitro Transfection and Expression (Optional)
Pass

Target Information

Full Name
Vascular Endothelial Growth Factor Receptor 2

Alternative Names
FLK1; CD309; VEGFR; KDR

Introduction
VEGFR-2 is a type IV receptor tyrosine kinase that serves as the primary mediator of the physiological and pathological effects of VEGF-A. It is predominantly expressed on vascular endothelial cells. In the context of oncology, VEGFR-2 is highly overexpressed on the blood vessels of solid tumors to facilitate neoangiogenesis. Targeting VEGFR-2 via CAR technology allows for a "dual-action" strike: directly starving the tumor by destroying its blood supply and potentially targeting VEGFR-2-expressing tumor cells themselves.

Targeting Diseases
Various Solid Tumors (especially highly vascularized ones like Renal Cell Carcinoma, Hepatocellular Carcinoma, Glioblastoma, and Melanoma)

UniProt ID
P35968

Gene ID
3791

Case Studies

Customer Reviews and Q&As

There are currently no customer reviews or questions for VivoCAR™ Anti-VEGFR-2 (TTAC-0001) h(CD28-41BB-CD3z) CAR saRNA (XS-0326-XU7). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.